Open AccessNo Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy
Author(s) -
Rajesh T. Gandhi,
Robert W. Coombs,
Ellen S. Chan,
Ronald J. Bosch,
Zheng Li,
David M. Margolis,
Sarah Read,
Beatrice Kallungal,
Ming Chang,
Erin Goecker,
Ann Wiegand,
Mary F. Kearney,
Jeffrey M. Jacobson,
Richard T. D’Aquila,
Michael M. Lederman,
John W. Mellors,
Joseph J. Eron
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31823fd1f2
Subject(s) - raltegravir , viremia , integrase inhibitor , virology , viral replication , viral load , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , medicine , immunology , virus
Controversy continues regarding the extent of ongoing viral replication in HIV-1-infected patients on effective antiretroviral therapy (ART). Adding an additional potent agent, such as raltegravir, to effective ART in patients with low-level residual viremia may reveal whether there is ongoing HIV-1 replication.